Workflow
鲁抗医药(600789) - 2024 Q1 - 季度财报
LKPCLKPC(SH:600789)2024-04-23 12:32

Financial Performance - The company's operating revenue for Q1 2024 was CNY 1,798,732,648.44, representing a year-on-year increase of 7.72%[2] - Net profit attributable to shareholders was CNY 67,307,574.42, up 47.32% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 53,371,705.45, reflecting a growth of 28.99%[2] - The total comprehensive income for Q1 2024 was CNY 70,966,706.12, compared to CNY 47,414,780.36 in Q1 2023, representing a year-over-year increase of approximately 49.6%[18] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.08, up from CNY 0.05 in Q1 2023, indicating a 60% increase[18] Cash Flow and Liquidity - The net cash flow from operating activities increased by 24.42%, amounting to CNY 162,849,287.26[2] - Cash inflow from operating activities for Q1 2024 was CNY 1,322,433,200.60, compared to CNY 1,104,889,360.12 in Q1 2023, reflecting a growth of about 19.7%[20] - Cash and cash equivalents at the end of Q1 2024 totaled CNY 540,092,784.49, up from CNY 323,314,673.48 at the end of Q1 2023, marking a significant increase of about 67.3%[22] - The net cash flow from financing activities for Q1 2024 was -CNY 58,395,522.27, an improvement from -CNY 137,996,819.86 in Q1 2023, indicating a reduction in cash outflow by approximately 57.7%[21] - Total cash outflow from investing activities in Q1 2024 was CNY 94,646,998.13, compared to CNY 54,985,097.24 in Q1 2023, which shows an increase of about 72%[21] Assets and Liabilities - Total assets at the end of Q1 2024 reached CNY 8,914,906,808.99, a 1.28% increase from the end of the previous year[3] - Total liabilities for Q1 2024 were ¥5,102,248,828.93, slightly up from ¥5,061,083,122.05 in Q1 2023[12] - The total equity attributable to shareholders reached ¥3,679,345,474.07 in Q1 2024, compared to ¥3,611,695,001.53 in Q1 2023, marking an increase of 1.9%[13] Research and Development - The company's R&D expenses in Q1 2024 amounted to ¥80,658,203.12, compared to ¥72,066,772.99 in Q1 2023, indicating an increase of 11.8%[16] Government Support - The company received government subsidies totaling CNY 10,270,500 during the reporting period, which were included in other income[4] Market Expansion - The company actively expanded its market presence, contributing to the significant increase in revenue and profit[5]